Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Zepbound is a dual GLP-1 and GIP receptor agonist, not a pure GLP-1 medication
- Its active ingredient is tirzepatide, the same molecule as Mounjaro, made by Eli Lilly
- Zepbound is FDA-approved for chronic weight management; Mounjaro covers the diabetes indication
- SURMOUNT-1 reported about 22.5 percent mean weight loss at the 15 mg dose, the largest effect among FDA-approved obesity medications
- Zepbound's December 2024 obstructive sleep apnea indication makes it the first GLP-1-class drug approved for OSA in adults with obesity
Direct answer
Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The GLP-1 receptor is part of its mechanism, but the molecule also activates the GIP receptor, which pure GLP-1 medications like Wegovy do not. The cleanest answer: Zepbound is in the incretin agonist family and shares clinical territory with GLP-1 medications, but technically belongs to its own sub-class as a dual agonist or "twincretin."
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The short answer with the necessary nuance
- Why Zepbound and Mounjaro carry different names
- How tirzepatide differs from semaglutide
- The SURMOUNT trial program in detail
- The sleep apnea indication and what it means
- Zepbound dosing and titration
- Side effects across the SURMOUNT program
- Insurance, cost, and the LillyDirect channel
- Compounded tirzepatide and the regulatory line
- Contrary view: is a "weight-loss drug" the right framing?
- Decision framework
- FAQ
- Sources
The short answer with the necessary nuance
The casual answer is yes: Zepbound is a GLP-1 medication in the broad sense. The precise answer is that Zepbound is a dual incretin agonist, activating both the GLP-1 receptor and the GIP receptor.
Patients shopping between Wegovy and Zepbound often use "GLP-1" to describe both. That works for setting expectations about side effects, injection schedule, and weight-loss trajectory. The drugs feel similar in use.
They differ in molecular target and in efficacy magnitude. If a clinical decision turns on which receptors are activated or what the projected weight loss looks like, the dual-agonist framing matters. If the question is just "what class is Zepbound in," the honest answer is "incretin agonist class, dual sub-type, not a pure GLP-1."
Why Zepbound and Mounjaro carry different names
The same molecule (tirzepatide) is marketed under two brand names by Eli Lilly. Mounjaro was approved first, in May 2022, for type 2 diabetes. Zepbound followed in November 2023 for chronic weight management.
The dual branding mirrors Novo Nordisk's split between Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for obesity). The pattern serves several purposes:
- Regulatory pathway. Separate trials supported separate FDA approvals. SURPASS for diabetes, SURMOUNT for obesity.
- Insurance coverage. Payers cover diabetes drugs and obesity drugs under different formulary tiers, with different prior-authorization criteria.
- Patient education. Titration schedules and counseling differ between diabetic and non-diabetic populations.
- Supply management. Separate brands let the manufacturer track demand and allocate production by indication.
The molecules are identical. A patient taking Zepbound is taking the same active ingredient as a patient taking Mounjaro, just under a different label with different titration guidance.
How tirzepatide differs from semaglutide
Both are weekly injectable peptides. Both activate the GLP-1 receptor. Both produce weight loss through reduced appetite and slower gastric emptying. The differences are pharmacological and clinical.
| Feature | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Receptor target | GLP-1 and GIP (dual agonist) | GLP-1 only (pure agonist) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Approved for obesity | November 2023 | June 2021 |
| Mean weight loss (highest dose) | ~22.5% (SURMOUNT-1) | ~14.9% (STEP 1) |
| Maximum dose | 15 mg weekly | 2.4 mg weekly |
| Half-life | ~5 days | ~7 days |
| Approved for OSA | Yes (December 2024) | No (as of May 2026) |
The most clinically meaningful difference is the magnitude of weight loss. Tirzepatide consistently outperformed semaglutide in head-to-head trials and across cross-trial comparisons. Whether this advantage holds in every individual patient depends on adherence, dose tolerated, and personal response.
The SURMOUNT trial program in detail
Zepbound's approval rested on the SURMOUNT clinical trial program:
SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine 2022). Tirzepatide vs placebo in 2,539 adults with obesity but without type 2 diabetes. Mean weight loss at 72 weeks: 15.0 percent (5 mg), 19.5 percent (10 mg), 20.9 percent (15 mg) vs 3.1 percent for placebo. The 22.5 percent figure often cited reflects per-protocol analysis at the 15 mg dose.
SURMOUNT-2. Tirzepatide in adults with obesity and type 2 diabetes. Weight loss was somewhat lower than in non-diabetic populations (typical for obesity medications) but still substantially exceeded placebo.
SURMOUNT-3. Tirzepatide added after intensive lifestyle intervention. Patients who reached at least 5 percent weight loss with lifestyle modification continued on tirzepatide or placebo. Additional weight loss with tirzepatide was substantial.
SURMOUNT-4 (Aronne et al., JAMA 2024). Withdrawal trial. After 36 weeks of open-label tirzepatide, patients were randomized to continued tirzepatide or placebo. Continued treatment maintained weight loss; placebo group regained substantial weight, similar to the pattern seen with semaglutide in STEP 4.
SURMOUNT-5. Direct head-to-head against semaglutide for obesity. Tirzepatide produced greater weight loss, confirming the cross-trial comparison from SURMOUNT-1 and STEP 1.
SURMOUNT-OSA. Tirzepatide in adults with obesity and moderate-to-severe obstructive sleep apnea. Significant reduction in apnea-hypopnea index, supporting the OSA indication added in December 2024.
The sleep apnea indication and what it means
In December 2024, the FDA approved an additional indication for Zepbound: treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on SURMOUNT-OSA.
The trial enrolled adults with obesity and OSA, with two arms: patients using positive airway pressure (PAP) therapy and patients unable or unwilling to use PAP. In both groups, tirzepatide reduced apnea-hypopnea index (AHI) more than placebo. Weight loss in the trial paralleled SURMOUNT-1, and the OSA improvement was strongly correlated with weight reduction.
This made Zepbound the first medication in the GLP-1-class family approved specifically for OSA. The indication does not replace PAP therapy in patients who tolerate it, but offers an alternative for patients who cannot use PAP or who want an adjunctive approach.
The indication is clinically significant because OSA is undertreated, often associated with obesity, and contributes to cardiovascular and metabolic complications. Treating both conditions with one therapy is appealing.
Zepbound dosing and titration
Zepbound is dosed once weekly by subcutaneous injection. The titration schedule:
- Weeks 1-4: 2.5 mg (starting dose, for titration only, not therapeutic)
- Weeks 5-8: 5 mg (first maintenance dose)
- Weeks 9-12: 7.5 mg (if needed for further effect)
- Weeks 13-16: 10 mg
- Weeks 17-20: 12.5 mg
- Week 21 and beyond: 15 mg (maximum maintenance dose)
Not every patient reaches 15 mg. Some achieve target weight loss at 5 or 10 mg. Some cannot tolerate dose escalation beyond a certain point due to GI side effects. The maintenance dose is individualized.
Each dose is delivered through a single-dose autoinjector pen. The pen contains 0.5 mL of solution. Injection sites rotate among abdomen, thigh, and upper arm.
Side effects across the SURMOUNT program
The side-effect profile in SURMOUNT trials matched what was seen in SURPASS:
- Nausea: 28 percent at 5 mg, 30 percent at 10 mg, 31 percent at 15 mg vs 9 percent placebo (SURMOUNT-1)
- Diarrhea: 19 percent at 5 mg, 21 percent at 10 mg, 23 percent at 15 mg vs 7 percent placebo
- Vomiting: 9 percent at 5 mg, 11 percent at 10 mg, 12 percent at 15 mg vs 2 percent placebo
- Constipation: 11 to 17 percent vs 6 percent placebo
- Abdominal pain: roughly 8 to 10 percent across doses
Discontinuation due to adverse events ranged from 4.3 percent to 7.1 percent across the active doses, vs 2.6 percent for placebo. Most discontinuations were related to GI tolerability.
The boxed warning for medullary thyroid carcinoma applies. Zepbound is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Other labeled warnings include severe gastrointestinal adverse reactions, acute pancreatitis, acute gallbladder disease, hypoglycemia in patients on insulin or insulin secretagogues, acute kidney injury (typically from dehydration), hypersensitivity reactions, retinopathy complications in patients with pre-existing diabetic retinopathy, suicidal behavior and ideation (monitoring recommended), and pulmonary aspiration during anesthesia (consider perioperative discontinuation).
Insurance, cost, and the LillyDirect channel
Zepbound's list price in 2026 sits around $1,059 per month at the highest dose, comparable to Wegovy's pricing. Most commercial insurance plans require prior authorization. Medicare Part D does not cover weight-loss medications under current law, though some plans cover Zepbound if prescribed for the OSA indication.
Eli Lilly launched the LillyDirect channel in 2024, offering self-pay options for Zepbound at reduced cost. The 2.5 mg and 5 mg single-dose vials (administered via syringe rather than pen) are priced lower than the pen versions, around $349 to $499 per month depending on dose and pharmacy. The vial format requires self-injection with a syringe, which some patients find less convenient.
The self-pay options matter because insurance coverage for obesity medications remains inconsistent. Patients meeting clinical criteria often face denial or step-therapy requirements that delay access.
Compounded tirzepatide and the regulatory line
Tirzepatide was on the FDA drug shortage list from December 2022 until October 2024. During the shortage, 503A compounding pharmacies were permitted to compound tirzepatide for individual patients. The market for compounded tirzepatide grew rapidly during 2023 and into 2024.
After the FDA declared the shortage resolved in October 2024, the broad shortage-based compounding pathway ended. A federal court challenge (the Outsourcing Facilities Association vs FDA case) briefly created uncertainty about the enforcement timeline, but the FDA's position prevailed.
As of May 2026, compounded tirzepatide is restricted to personalized prescribing under 503A rules, where a specific patient need cannot be met by the commercial product (for example, a documented allergy to an inactive ingredient, or a need for a non-commercial dose). Volume has declined substantially compared with 2023-2024 levels.
Compounded tirzepatide is not Zepbound. The active ingredient is the same molecule, but compounded preparations have not undergone FDA review for purity, potency, sterility, or stability. They are not interchangeable with Zepbound and should not be marketed as equivalent.
Contrary view: is a "weight-loss drug" the right framing?
Zepbound is widely discussed as a weight-loss drug. The framing is accurate but incomplete.
The drug's full effect profile includes glycemic improvement, blood pressure reduction, lipid changes, OSA improvement, and emerging evidence for cardiovascular risk reduction. Reducing all of this to "weight loss" understates the metabolic intervention.
An alternative framing: Zepbound is a metabolic medication. It treats obesity-related dysregulation across multiple systems. Weight loss is one outcome, alongside improvements in glucose, sleep, and cardiovascular markers.
The clinical implication: patients who do not lose dramatic weight on Zepbound may still gain meaningful health benefits. Some patients see weight plateau in the 5 to 10 percent range but have substantial reductions in blood pressure, A1C, and apnea-hypopnea index. Categorizing the drug solely by weight outcome misses these patients' real benefits.
The counterargument: weight loss is the FDA-approved indication and the primary reason patients seek the drug. Marketing and clinical conversation appropriately focus on that endpoint. Other benefits are real but secondary in most prescribing contexts.
The middle position is to frame Zepbound as a metabolic medication primarily indicated for chronic weight management, with documented effects on multiple metabolic systems. This framing supports realistic patient expectations and appropriate clinical use.
Decision framework
If you are choosing between Zepbound and Wegovy:
- Zepbound generally produces greater weight loss in clinical trials.
- Side-effect profiles are similar; Zepbound shows somewhat higher GI rates at top doses.
- Insurance coverage and prior authorization may drive the practical decision.
If you have OSA and obesity:
- Zepbound is the only GLP-1-class drug with an FDA-approved OSA indication as of May 2026.
- The drug supplements but does not replace PAP therapy in patients who tolerate it.
If you have type 2 diabetes:
- Mounjaro is the FDA-approved tirzepatide product for diabetes. Zepbound for diabetes is off-label.
- Insurance coverage typically follows the labeled indication.
If you are considering compounded tirzepatide:
- Compounded tirzepatide is not Zepbound. It is a separate, non-FDA-approved product.
- Verify that the compounding pharmacy is state-licensed and operates under 503A rules.
- Discuss with your provider whether compounded therapy fits your situation.
FAQ
Is Zepbound a GLP-1? Zepbound activates the GLP-1 receptor but is a dual GLP-1/GIP receptor agonist, not a pure GLP-1 RA. The casual answer is yes; the precise answer is "dual incretin agonist."
Is Zepbound the same as Mounjaro? Same molecule (tirzepatide). Different brand, different approved indication (obesity vs diabetes). Made by Eli Lilly.
Is Zepbound a GLP-1 like Wegovy? Both are weekly injectables for obesity. Wegovy is a pure GLP-1 RA (semaglutide). Zepbound is a dual GLP-1/GIP agonist (tirzepatide). Tirzepatide produces greater weight loss in trials.
How does Zepbound cause weight loss? By activating GLP-1 and GIP receptors in the pancreas, gut, and brain. Reduced appetite, slowed gastric emptying, and increased satiety contribute.
Who can take Zepbound? Adults with BMI 30 or higher (obesity), or BMI 27 or higher (overweight) with at least one weight-related comorbidity. A clinician evaluates each patient.
When was Zepbound approved? November 8, 2023, for chronic weight management. The OSA indication was added in December 2024.
What is the dosing for Zepbound? Once-weekly subcutaneous injection. Starts at 2.5 mg, titrates to 5, 7.5, 10, 12.5, or 15 mg weekly. Maximum dose is 15 mg.
Is compounded tirzepatide the same as Zepbound? No. Compounded tirzepatide is not FDA-approved. It uses the same molecule but is prepared by 503A pharmacies under individual prescriptions.
Does Zepbound work for diabetes? Tirzepatide reduces HbA1c effectively. However, the FDA-approved tirzepatide product for diabetes is Mounjaro. Zepbound use for diabetes is off-label.
How much weight will I lose on Zepbound? Trial averages: about 15 to 21 percent of body weight on doses 5 to 15 mg over 72 weeks. Individual results vary substantially based on adherence, diet, exercise, and biological response.
Can I stop Zepbound after I reach my goal? SURMOUNT-4 showed substantial weight regain after discontinuation. Most patients regain a significant fraction of lost weight within a year of stopping. Long-term use is generally required to maintain weight loss.
How much does Zepbound cost? List price around $1,059 per month at high dose. Insurance coverage varies. The LillyDirect single-dose vial program offers lower self-pay pricing for some doses.
Sources
- FDA Prescribing Information. Zepbound (tirzepatide). Updated 2024.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
- Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
- Wadden TA et al. Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity (SURMOUNT-3). Nature Medicine. 2023.
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. 2024.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- FDA Drug Shortages Database. Tirzepatide Injection. 2022-2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2025.
- Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting consumers with independent licensed healthcare providers and U.S.-based pharmacies. We do not provide medical care directly, manufacture drugs, or dispense prescriptions. Treatment decisions rest with the prescribing clinician.
Compounded Medication Notice. Compounded tirzepatide is not Zepbound and is not FDA-approved. State-licensed 503A pharmacies prepare compounded tirzepatide in response to individual prescriptions when clinical circumstances warrant. The FDA has not reviewed compounded preparations for safety, purity, stability, or efficacy.
Results Disclaimer. Reported clinical trial averages reflect controlled study populations. Real-world outcomes vary depending on dose tolerance, baseline weight, diet, exercise, adherence, and individual physiology. Discontinuing treatment typically results in weight regain.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda and Victoza are also registered trademarks of Novo Nordisk. FormBlends is not affiliated with or endorsed by Eli Lilly, Novo Nordisk, or any other manufacturer named in this content.